VRCA — Verrica Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $60.64m
- $50.84m
- $35.58m
Verrica Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Verrica Pharma rises on preliminary results from skin cancer treatment, Q2 results
Brief: Verrica Pharma Announces Preliminary Topline Results From Part 2 Of Phase 2 Clinical Study Of VP-315
Verrica Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview
Verrica Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Verrica Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview
Verrica Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Verrica's Skin Infection Drug Receives New Chemical Entity Status, Orange Book Listing From US FDA
Verrica Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Verrica Pharmaceuticals Q4 basic EPS USD -0.53
Verrica Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview
Verrica Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer For "False Advertising And Unfair Competition"
Brief: Verrica Pharmaceuticals Receives Permanent J-Code (J7354) For YCANTH From Centers For Medicare And Medicaid Services
Ligand Pharma up after at-home viral skin infection treatment gets US approval
U.S. STOCKS ON THE MOVE-First Solar, Battalion Oil, Cano Health
Verrica Pharma gains as skin disease drug study in Japan shows promise